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Abstract
Background: In recent randomized controlled trials (RCTs) intra-arterial treatment (IAT) has been proven effective and
safe for patients with acute ischemic stroke (AIS). So far, there seemed to be no interaction between older age (>80) and
main treatment effect. We studied the association of older age with outcome and adverse events after IAT in a cohort of
intra arterially treated patients.
Methods and findings: Data from all AIS patients with proven proximal anterior circulation cerebral artery occlusion
who were intra arterially treated between 2002 until the start of the MR CLEAN trial were studied retrospectively. Duration
of the procedure, recanalization (Thrombolysis In Cerebral Infarction score (TICI)), early neurological recovery (i.e. decrease
on NIHSS of≥ 8 points) after one week or at discharge, good functional outcome at discharge by modified Rankin Scale
(mRS≤ 2) and the occurrence of neurological and non-neurological adverse events were assessed and the association
with age was investigated. In total 315 patients met our inclusion criteria. Median age was 63 years (range 22–93) and 17
patients (5.4 %) were over 80. Age was inversely associated with good functional outcome (adjusted Odds Ratio (aOR) 0.
80, 95 % CI: 0.66–0.98) for every 10 years increase of age. Age was not associated with longer duration of the procedure,
lower recanalization rate or less early neurological recovery. The risk of all adverse events (aOR 1.27; 95 % CI: 1.08–1.50)
and non-neurological adverse events (aOR 1.34; 95 % CI: 1.11–1.61) increased, but that of peri-procedural adverse events
(aOR 0.79; 95 % CI: 0.66–0.94) decreased with age.
Conclusion: Higher age is inversely associated with good functional outcome after IAT in patients with AIS. However,
treatment related adverse events are not related to age. These findings may help decision making when considering
treatment of older patients with AIS.
Keywords: Intra-arterial treatment, Older age, Acute ischemic stroke
Background
Stroke is one of the leading causes of death and disability.
Risk of stroke increases with age [1]. Higher age is often
an exclusion criterion in randomized trials especially in
those evaluating acute treatment. This applied to the first
trials evaluating the effect of intravenous thrombolysis [2].
Later studies and meta-analyses, however, demonstrated
the effect of intravenous alteplase in older patients [3–5].
Recently, the safety and efficacy of intra-arterial treatment
(IAT) was established in several large trials [5–9]. Although
not all trials included patients aged >80 years [6, 7], in those
intervention trials that included older patients treatment
effect seemed similar in the young and the old, but the
proportions of older patients were small, suggesting selec-
tion bias [8, 10, 11]. In older patients, longer procedure
time and higher complication rates may be expected, due
to technical difficulties such as advanced atherosclerosis
and vessel tortuosity. Low quality collateral circulation and
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brain tissue vulnerability may lead to delayed or diminished
neurological recovery.
We studied the association between age and procedure
duration, rate of recanalization, occurrence of adverse
events, neurological recovery and functional outcome after
IAT in patients with acute ischemic stroke (AIS) due to a
large vessel occlusion in the anterior circulation. We ana-
lysed data from the Multicenter Randomized CLinical trial
of Endovascular treatment for Acute ischemic stroke in
the Netherlands (MR CLEAN) pretrial registry.
Methods
Patients
In this cohort study, we selected patients with a clinical
diagnosis of AIS similar to criteria of MR CLEAN [12]
from the prospective patient registries of the participating
centers. Approval for this retrospective study was obtained
by the central medical ethical committee of the Erasmus
University Medical Center Rotterdam and because of the
retrospective nature of the study no written informed con-
sent was obliged from each participant. Patients were
treated intra-arterially in 16 large stroke hospitals in The
Netherlands between October 2002 and start of participa-
tion of the hospital in the MR CLEAN trial, between 2010
and 2012. We selected all patients with a neurological
deficit on the National Institutes of Health Stroke Scale
(NIHSS) of at least two points. Intracranial haemorrhage
was ruled out by Computed Tomography (CT) or Magnetic
Resonance Imaging (MRI). Intracranial arterial occlusion
was confirmed by Computed Tomography Angiography
(CTA), Magnetic Resonance Angiography (MRA) or Digital
Subtraction Angiography (DSA) and was located in the
distal part of the internal carotid artery, the middle cerebral
artery (M1 and M2 segment), or the anterior cerebral artery
(A1 segment). Intra-arterial treatment had to be started
within 6 h from onset of symptoms and patients had to be
18 years or older. There was no upper age limit. Patients
were excluded if systolic blood pressure was > 185 mmHg
or diastolic blood pressure was > 110 mmHg, if blood glu-
cose level was < 2.7 or > 22.2 mmol/L, if intravenous treat-
ment with alteplase was given in a dose exceeding 0.9 mg/
kg or 90 mg, or if intravenous alteplase was given despite
contraindications such as major surgery, gastro-intestinal
bleeding or urinary tract bleeding within the previous
2 weeks, or arterial puncture at a non-compressible site
within the previous 7 days. Specific exclusion criteria ap-
plied for patients treated mechanically or with intra-arterial
thrombolysis. Patients treated with mechanical devices were
excluded when there was laboratory evidence of coagula-
tion abnormalities (platelet count < 40*109/l, APTT > 50 s
or INR > 3.0). Patients treated with intra-arterial thromboly-
sis were excluded when the platelet count was < 90 * 109/L,
APTT > 50 s, or INR > 1.7.
We obtained all clinical and radiological data of the pa-
tients who were prospectively registered in the participating
centres and all patient data were anonymized prior to ana-
lysis. Missing values of NIHSS were reconstructed with the
help of a validated algorithm [13].
Intervention
Intra-arterial treatment consisted of arterial catheterization
with a microcatheter to the level of occlusion. At the level
of the occlusion the interventionist could decide to deliver
a thrombolytic agent, perform mechanical thrombectomy
or both. This choice was left to the discretion of the inter-
ventionist. Pre- and post-intervention angiograms were
made to assess location and grade of occlusion and final
recanalization.
Outcomes
We tabulated baseline risk factors and results by tertiles
of age.
Functional outcome was assessed by means of the modi-
fied Rankin Scale (mRS) at discharge. Good functional out-
come was defined as a mRS score of 0, 1 or 2. Neurological
status after the intervention was evaluated with the NIHSS,
assessed at one week after the procedure (or at discharge in
case discharge was within the first week). Early neurological
recovery was defined as a decrease on the NIHSS of 8
points or more after one week or at discharge compared
with baseline NIHSS.
The duration of the procedure was determined by the
time interval between the first and last angiographic
series plus 5 min. Occlusion status was assessed with the
TICI score, at the start and at the end of the procedure.
Recanalization was defined as a TICI score of 2b or 3 at
the end of the procedure. Digital subtraction angiography
images were assessed by one of three experienced neuro-
radiologists (PB, GL, SJ). They were blinded for clinical
data of the patient, and did not assess angiograms from
their own centre.
Adverse events
We defined symptomatic intracerebral haemorrhage
(SICH) as intraparenchymal blood on cranial CT being
compatible with neurological deterioration. Symptomatic
haemorrhagic transformation was defined as CT detected
haemorrhagic transformation of the acute infarct accom-
panied by neurological deterioration. Recurrent ischemic
stroke, stuttering stroke, brain herniation and craniotomy
accompanied with neurological deterioration were all clus-
tered as progression of ischemic stroke.
Adverse events were categorized as neurological ad-
verse events, neurological serious adverse events, non-
neurological adverse events and peri-procedural adverse
events. Neurological adverse events were any symptomatic
intracerebral haemorrhage, haemorrhagic transformation,
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progression of ischemic stroke, intracranial haemorrhage
and transient neurological dysfunction including seizures.
Neurological serious adverse events were symptomatic
intracranial haemorrhage, haemorrhagic transformation of
the infarct and progression of ischemic stroke with an
increase on the NIHSS of 4 points or more. Non-
neurological adverse events, without neurological sequelae,
were pneumonia, urinary tract infections, cardiac rhythm
disturbances, and other complications. Other complications
included pulmonary embolism, cerebral venous thrombosis,
bacteraemia, use of antibiotics without a confirmed infec-
tion, oral mycosis, delirium, acute kidney failure and falls.
Peri-procedural adverse events included development of
distal micro-emboli, technical problems including unfolding
of stent retriever, iatrogenic damage of arterial vessel wall,
groin hematoma and peri-procedural seizures.
Statistical analysis
We analysed the association of age with good functional
outcome (mRS 0–2) with regression models expressed
as odds Ratio (OR). Multiple linear regression was used
to determine the association of age with the duration of
the procedure and the neurological outcome (NIHSS)
after the procedure. We analyzed the association of age
with recanalization and occurrence of adverse events,
with logistic regression models. In all regression models,
age was a continuous variable, and effect parameters
were expressed per 10 years of age. Precision of effect
estimates was described by 95 % confidence intervals.
We always adjusted for sex, onset to treatment time,
stroke severity at baseline (NIHSS), use of a retrievable
stent and presence of intracranial carotid T occlusions.
Values missing at random were imputed with their mean
or modus. Statistical analyses were carried out with Stata
statistical software (release 12.0 College Station, Texas).
Results
During the study period 529 patients with ischemic stroke
were treated with IAT in the participating centers. Of
these, 160 had a posterior circulation stroke and were not
included in this study. From the remaining 369 patients,
we excluded 19 (5.1 %) who underwent IAT more than
6 h after symptom onset, 15 (4.1 %) because of AIS
secondary to a surgical procedure, 1 patient (0.3 %) in
whom carotid artery dissection was the cause and 1 pa-
tient (0.3 %) who had a distal anterior circulation cerebral
artery occlusion (M3 segment). We also excluded 2
patients (0.5 %) because of age < 18 years, 4 patients
(1.0 %) because systolic blood pressure > 185 mmHg or
diastolic blood pressure > 110 mmHg, 11 patients (3.0 %)
because of coagulation disturbances and 1 patient (0.3 %)
because of pre-treatment glucose level > 22.2 mmol/l.
As a result 315 patients were included. Median age of
the included patients was 63 years (range 22–93) and 17
patients (5 %) were older than 80. Median NIHSS was
16 (IQR 12–18) and 245 patients (78 %) were treated
with intravenous alteplase prior to IAT (Table 1).
IAT consisted of stent thrombectomy in 132 (42 %).
The median duration of the procedure was 116 min
(IQR 80–153). At the end of the procedure a TICI 2b or
3 was reached in 119 patients (43 %) (see Table 2). SICH
occurred in 23 patients (7.0 %) and prevalence of SICH
was highest in the third age tertile (10/96, 10 %). Mortal-
ity was higher in older patients, 22 % in the third tertile
versus 9 % in the first tertile.
We found a significant inverse association between
age and good functional outcome (mRS 0–2) (aOR
0.80; 95 % CI: 0.66–0.98) for every 10 years increase of
age. Furthermore, we found a significant association
between age and the occurrence of all adverse events
(aOR 1.27, 95 % CI: 1.08–1.50) as well as the occur-
rence of non-neurological adverse events (aOR 1.34,
Table 1 Baseline characteristics of the included patients
Overall Tertile 1 Tertile 2 Tertile 3
22–93 years 22–55 years 56–70 year 71–93 years
Number of patients 315 106 113 96
Age, median (IQR) 63 (52–72) 48 (40–52) 64 (60–68) 77 (73–80)
Male sex, n (%) 168 (53 %) 52 (49 %) 75 (66 %) 41 (43 %)
Systolic blood pressure, mean (SD) 146 (23) 138 (21) 149 (24) 152 (20)
Diastolic blood pressure, mean (SD) 82 (16) 78 (16) 85 (15) 84 (17)
Stroke severity at admission (NIHSS) mean (SD)a 16 (6.0) 15 (5.0) 16 (5.0) 16 (7.0)
Prior treatment with intravenous rtPA, n (%)b 245 (78 %) 77 (73 %) 91 (81 %) 75 (80 %)
Time from onset symptoms to intra-arterial treatment (minutes), mean (SD)c 93 (58) 96 (70) 87 (67) 77 (53)
Use of stent, n (%)d 132 (42 %) 41 (39 %) 52 (46 %) 39 (41 %)
Carotid T top occlusion, n (%)e 25 (8.0 %) 11 (10 %) 11 (10 %) 3 (3.0 %)
SD standard deviation, IQR interquartile range, ER emergency room
a65 unknown (21 %); b13 unknown (4.1 %); c177 unknown (56 %); d4 unknown (0.6 %); e2 unknown (0.6 %)
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95 % CI: 1.11–1.61) (Table 3). Age was significantly
associated with less peri-procedural adverse events
(aOR 0.79, 95 % CI: 0.66–0.94) (Table 4). We found no
association between age and neurological recovery after
IAT (aOR 0.88, 95 % CI: 0.75–1.04). No associations
were observed between age and duration of the proced-
ure (regression coefficient −2.96 95 % CI: −7.35–1.44),
recanalization (aOR 0.94, 95 % CI: 0.79–1.11), neuro-
logical serious adverse events (aOR 1.22, 95 % CI: 0.96–
1.56) and neurological adverse events (aOR 1.05, 95 %
CI: 0.89–1.24).
Discussion
In the present study we show that the likelihood of good
functional outcome after IAT was inversely associated with
age, whereas we did not find an increased risk for neuro-
logical (serious) adverse events after IAT in older patients
although the likelihood of developing non-neurological
adverse events increased with age. Interestingly, the risk of
developing peri-procedural adverse events decreased with
increasing age.
Our results are in line with recent studies that also
showed lower rates of good clinical outcome in elderly
Table 2 Clinical and radiological outcomes in patients with IAT for acute ischemic stroke caused by proximal arterial intracranial
occlusion of the anterior circulation by age
Overall Tertile 1 Tertile 2 Tertile 3 P for
trend22–93 years 22–55 years 56–70 year 71–93 years
N patients 315 106 113 96
Procedural duration in minutes, median (IQR) 116 125 110 116 0.19
(80–153) (81–160) (78–143) (82–158)
Recanalization (TICI 2b and TICI 3) 119 (43 %) 41 (34 %) 45 (38 %) 33 (28 %) 0.46
TICI 0, n (%) 38 (14 %) 12 (12 %) 12 (12 %) 14 (17 %)
TICI 1, n (%) 18 (6.0 %) 10 (10 %) 5 (5.0 %) 3 (4.0 %)
TICI 2a, n (%) 103 (37 %) 36 (36 %) 35 (36 %) 32 (39 %)
TICI 2b, n (%) 36 (13 %) 13 (13 %) 17 (18 %) 6 (7.0 %)
TICI 3, n (%) 83 (30 %) 28 (28 %) 28 (29 %) 27 (33 %)
NIHSS after IAT, mean (SD) 13 (12) 12 (10) 13 (11) 15 (13) 0.14
Neurological recovery (decrease in NIHSS of 8 points or more), n (%) 133 (42 %) 47 (44 %) 49 (43 %) 37 (39 %)
Functional outcome, mRS, n (%) 0.03
mRS 0–1, n (%) 37 (12 %) 15 (14 %) 9 (8 %) 13 (14 %)
mRS 0–2, n (%) 78 (25 %) 29 (27 %) 27 (24 %) 22 (23 %)
mRS 0–3, n (%) 132 (42 %) 46 (43 %) 49 (43 %) 37 (39 %)
mRS 0–4, n (%) 222 (70 %) 80 (75 %) 82 (73 %) 60 (63 %)
mRS 0–5, n (%) 261 (83 %) 96 (91 %) 92 (81 %) 73 (76 %)
Death, n (%) 51 (16 %) 10 (9 %) 20 (18 %) 21 (22 %) 0.01
All adverse events, n (%) 177 (56 %) 46 (43 %) 71 (63 %) 60 (63 %) 0.004
Serious adverse events, n (%) 47 (15 %) 13 (12 %) 18 (16 %) 16 (17 %) 0.11
Symptomatic intracranial hemorrhage, n (%) 23 (7.0 %) 5 (5.0 %) 8 (7.0 %) 10 (10 %)
Hemorrhagic transformation infarct, n (%) 6 (2.0 %) 2 (2.0 %) 4 (4.0 %) 0 (0.0 %)
Progression of ischemic stroke, n (%) 32 (10 %) 8 (8.0 %) 13 (12 %) 11 (12 %)
Neurological adverse events, n (%) 119 (38 %) 38 (36 %) 48 (42 %) 33 (34 %) 0.60
Asymptomatic intracranial hemorrhage 22 (7 %) 2 (2.0 %) 15 (13 %) 5 (5.0 %)
hemorrhage, n (%)
Seizures, n (%) 16 (5.0 %) 4 (4.0 %) 4 (4.0 %) 8 (8.0 %)
Non-neurological adverse events, n (%) 101 (32 %) 20 (19 %) 40 (35 %) 41 (43 %) 0.002
Pneumonia, n (%) 41 (13 %) 9 (8.0 %) 16 (14 %) 16 (17 %)
Urinary tract infection, n (%) 18 (6.0 %) 5 (5.0 %) 5 (4.0 %) 8 (8.0 %)
Cardiac arrhythmias, n (%) 35 (11 %) 3 (3.0 %) 17 (15 %) 15 (16 %)
Other, n (%) 29 (9.0 %) 8 (8.0 %) 9 (8.0 %) 12 (13 %)
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stroke patients treated with IAT. These retrospective non-
randomized studies do not allow conclusions about the
treatment effect of IAT in older aged patients. Therefore
results of randomized controlled trials are needed. Several
large randomized controlled trials have investigated the
effect of IAT in AIS, but only three of these had no upper
age limit [10, 14, 15]. In two of those no effect modifica-
tion by age was present [8, 10], but a more refined analysis
on age has not been performed so far. Selection bias, by
including only the relatively healthier older patients in the
trials, cannot be excluded.
Our study has several limitations. First, although patients
were prospectively registered, all patient data had to be
assessed retrospectively from the hospital records. However,
we are confident that all intra-arterially treated patients are
included and that there are no missing data on important
medical information as the occurrence of adverse events,
because all centers kept prospective registries of intra-
Table 3 Age in association with clinical neurological and radiological outcomes. Effect parameters are expressed per 10 years of age
Association Unadjusted Sex adjusted Fully adjusted
Intervention
Duration of procedure, minutes BC −2.80 −2.80 −2.96
[−7.10 to 1.45] [−7.10 to 1.45] [−7.35 to 1.44]
Recanalization (TICI 2b-3) OR 0.94 0.94 0.94
[0.80 to 1.11] [0.8. to 1.11] [0.79 to 1.11]
Clinical outcome
Neurological recovery (decrease on NIHSS > 7 points) OR 0.92 0.92 0.88
[0.79 to 1.08] [0.79 to 1.08] [0.75 to 1.04]
Functional outcome, mRS 0-2 OR 0.85 0.85 0.80
[0.71 to 1.01] [0.71 to 1.01] [0.66 to 0.98]
Safety outcome
Peri-procedural adverse events OR 0.79 0.79 0.79
[0.67 to 0.93] [0.67 to 0.93] [0.66 to 0.94]
All adverse events OR 1.27 1.27 1.27
[1.08 to 1.49] [1.08 to 1.49] [1.08 to 1.50]
Neurological serious adverse events OR 1.04 1.04 1.05
[0.89 to 1.22] [0.89 to 1.22] [0.89 to 1.24]
Neurological adverse events OR 1.04 1.04 1.05
[0.89 to 1.22] [0.89 to 1.22] [0.89 to 1.24]
Non-neurological adverse events OR 1.37 1.37 1.34
[1.14 to 1.64] [1.14 to 1.64] [1.11 to 1.61]
BC beta coefficient, OR odds ratio. Fully adjusted means adjusted for; sex, onset to treatment time, stroke severity at baseline (NIHSS), use of a retrievable stent,
presence of a carotid T occlusion
Table 4 Clinical and radiological outcome in patients younger than 80 years and patients 80 years or over
<80 years ≥80 years
N patients 298 17
Procedural duration in minutes, median (IQR) 121 (55) 108 (54)
Recanalization (TICI 2b and TICI 3) 113 (43 %) 6 (46 %)
Neurological recovery (decrease in NIHSS of 8 points or more), n (%) 9 (53 %) 8 (47 %)
Good functional outcome at discharge, mRS 0–2, n (%) 75 (25 %) 3 (18 %)
Death, n (%) 47 (16 %) 4 (26 %)
All adverse events, n (%) 164 (55 %) 13 (76 %)
Non-neurological adverse events, n (%) 91 (31 %)* 10 (59 %)*
Neurological adverse events, n (%) 113 (38 %) 6 (35 %)
Neurological serious adverse events, n (%) 44 (15 %) 3 (18 %)
*p = 0.02
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arterially treated patients and our research team had access
to all data. Second, we did not systematically register co-
morbidity, such as previous myocardial infarction and
previous ischemic stroke. However, it is well known that
comorbidity increases with age and this may explain some
of the excess mortality and poor outcome. Third, the rela-
tively low percentage of recanalization might be explained
by the relative low percentage of treatments with latest
generation thrombectomy devices, as these devices only
entered the market halfway the inclusion period [16]. These
so called stent retrievers have a proven better recanalization
success rate than the first generation devices [11, 17].
Fourth, the small percentage of patients above 80 years old
(5 %) in this cohort suggests a strong selection bias. This
might explain the lower peri-procedural adverse event rate
in the older patients: exclusion from treatment of patients
with hostile vessels is more likely when patients are older.
Fifth, the lack of a reference population to compare with
and to know if there was a selection bias for the higher
aged subjects who underwent IAT. However, the goal of
this study was to describe a relation between age and out-
come in intra-arterially treated patients to assess whether
un upper age limit in randomized controlled trials is
indicated. To have the best comparison between age
and treatment effect in age in IAT we need the results
of randomized controlled trials.
Our study has several strengths: First, we could make
use of prospective registries of the participating hospitals
in which all IAT treated patients were documented. As
such, all patients treated in these centers are included in
this study. Second, all stroke intervention centers in the
Netherlands participated in this study what makes it very
unlikely that more than just a few patients were not regis-
tered and included in this study. And thirdly, all participat-
ing centers were comprehensive stroke services with a
central function for acute stroke treatment for regional
hospitals.
Conclusion
In summary, we confirm that older age is inversely associ-
ated with good functional outcome after IAT in patients
with AIS. Furthermore age is associated with increased
non-neurological adverse events. Our results, however, do
not confirm an increased risk of treatment related events
nor an increase of neurological adverse events. This might
explain the findings in recent RCTs that older age does not
interact with treatment effect of IAT. Knowledge about the
effect of age on clinical outcome, procedure related features
and adverse events of IAT may enhance proper decision
making in treatment of older patients with AIS.
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